HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

vupanorsen

an antisense oligonucleotide targeting hepatic ANGPTL3 mRNA for degradation

Networked: 7 relevant articles (2 outcomes, 2 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Nucleic Acids, Nucleotides, and Nucleosides: 1
- Nucleotides: 15763
  - Polynucleotides: 218
    - Oligonucleotides: 5145
      - vupanorsen: 7

Experts

1.	Bartlett, Victoria J: 2 articles (12/2021 - 10/2020)
2.	Hurh, Eunju: 2 articles (12/2021 - 10/2020)
3.	Karwatowska-Prokopczuk, Ewa: 2 articles (12/2021 - 10/2020)
4.	Bergmark, Brian A: 1 article (01/2022)
5.	Bramson, Candace R: 1 article (01/2022)
6.	Curto, Madelyn: 1 article (01/2022)
7.	Hegele, Robert A: 1 article (01/2022)
8.	Jevne, Alexandra: 1 article (01/2022)
9.	Kuder, Julia F: 1 article (01/2022)
10.	Marston, Nicholas A: 1 article (01/2022)

Related Diseases

1.	Hypertriglyceridemia 01/01/2022 - "Several emerging treatments for hypertriglyceridemia include apo C-III antagonists (volanesorsen, AKCEA-APOCIII-LRx and ARO-APOC3) and angiopoietin-like 3 antagonists (evinacumab, vupanorsen and ARO-ANG3); efficacy observed in clinical trials of these agents in nonlipodystrophic patients with severe hypertriglyceridemia suggests that they may also be helpful in lipodystrophy. "
2.	Lipodystrophy 01/01/2022 - "Several emerging treatments for hypertriglyceridemia include apo C-III antagonists (volanesorsen, AKCEA-APOCIII-LRx and ARO-APOC3) and angiopoietin-like 3 antagonists (evinacumab, vupanorsen and ARO-ANG3); efficacy observed in clinical trials of these agents in nonlipodystrophic patients with severe hypertriglyceridemia suggests that they may also be helpful in lipodystrophy. "
3.	Heart Failure 10/03/2020 - "The studies reviewed include clinical trials on novel RNA interference-based lipid-lowering therapies AKCEA-APOCIII-LRx and vupanorsen (AKCEA-ANGPTL3-LRx); the EVAPORATE trial assessing the effects of icosapent ethyl on coronary plaque volume progression; the LoDoCo2 trial evaluating the efficacy of low-dose colchicine in cardiovascular disease risk reduction among patients with chronic coronary artery disease; as well as the EMPEROR-Reduced trial evaluating cardiovascular and renal outcomes with empagliflozin in patients with heart failure and reduced ejection fraction. "
4.	Coronary Artery Disease (Coronary Atherosclerosis) 10/03/2020 - "The studies reviewed include clinical trials on novel RNA interference-based lipid-lowering therapies AKCEA-APOCIII-LRx and vupanorsen (AKCEA-ANGPTL3-LRx); the EVAPORATE trial assessing the effects of icosapent ethyl on coronary plaque volume progression; the LoDoCo2 trial evaluating the efficacy of low-dose colchicine in cardiovascular disease risk reduction among patients with chronic coronary artery disease; as well as the EMPEROR-Reduced trial evaluating cardiovascular and renal outcomes with empagliflozin in patients with heart failure and reduced ejection fraction. "
5.	Cardiovascular Diseases (Cardiovascular Disease) 10/03/2020 - "The studies reviewed include clinical trials on novel RNA interference-based lipid-lowering therapies AKCEA-APOCIII-LRx and vupanorsen (AKCEA-ANGPTL3-LRx); the EVAPORATE trial assessing the effects of icosapent ethyl on coronary plaque volume progression; the LoDoCo2 trial evaluating the efficacy of low-dose colchicine in cardiovascular disease risk reduction among patients with chronic coronary artery disease; as well as the EMPEROR-Reduced trial evaluating cardiovascular and renal outcomes with empagliflozin in patients with heart failure and reduced ejection fraction. "

Related Drugs and Biologics

1.	Angiopoietins
2.	Lipids
3.	Apolipoprotein C-III
4.	Colchicine
5.	empagliflozin
6.	eicosapentaenoic acid ethyl ester
7.	evinacumab
8.	Messenger RNA (mRNA)
9.	Apolipoproteins
10.	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)

Related Therapies and Procedures

1.	Therapeutics